ClinicalTrials.gg
RecruitingNCT06818643Updated Nov 13, 2026

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

A Phase 1/2 interventional study of MK-3120 in Advanced Solid Tumors and Malignant Neoplasm, sponsored by Merck Sharp & Dohme LLC. Recruiting at 49 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 13, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

02

Conditions studied

  • Advanced Solid Tumors
  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 270 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed advanced (unresectable and/or ) solid tumor and has received or been intolerant to all available treatments
  • If (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)
  • If surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • If virus (HCV) infected, must have undetectable HCV viral load

Exclusion criteria

Exclusion Criteria:

  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease
  • Has uncontrolled significant cardiovascular disease or cerebrovascular disease
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
  • Is -positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional that is progressing or has required active treatment within the past 2 years
  • Known active central nervous system (CNS) and/or carcinomatous meningitis
  • Active infection requiring systemic therapy, with exceptions
  • History of (noninfectious) pneumonitis/interstitial lung disease that required or has current pneumonitis/interstitial lung disease
  • Has or infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Arm 1 Dose level 1

    Participants receive MK-3120 at dose level 1 as per the schedule specified in the arm.

    Biological: MK-3120

  • Experimental
    Arm 2 Dose level 2

    Participants receive MK-3120 at dose level 2 as per the schedule specified in the arm.

    Biological: MK-3120

Interventions

  • BiologicalMK-3120

    IV infusion

    Also known as: SKB410

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.

    Time frame: Up to approximately 19 months

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

    Time frame: Up to approximately 18 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as Assessed by the Investigator

    ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the investigator per RECIST 1.1.

    Time frame: Up to approximately 48 months

07

Study locations

24 of 49 sites recruiting
  • The University of Alabama at Birmingham ( Site 1005)
    Birmingham, Alabama 35249, United States
    Recruiting
    • Study Coordinator · Contact205-934-4199
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)
    Miami, Florida 33136, United States
    Recruiting
    • Study Coordinator · Contact305-243-5302
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Study Coordinator · Contact551-996-5900
  • NEXT Oncology ( Site 1010)
    Austin, Texas 78758, United States
    Recruiting
    • Study Coordinator · Contact737-610-5202
  • NEXT Oncology ( Site 1011)
    Houston, Texas 77054, United States
    Recruiting
    • Study Coordinator · Contact832-384-7912
  • NEXT Oncology ( Site 1012)
    Irving, Texas 75039, United States
    Recruiting
    • Study Coordinator · Contact972-893-8800
  • Virginia Commonwealth University ( Site 1008)
    Richmond, Virginia 23219, United States
    Recruiting
    • Study Coordinator · Contact804-828-7999
  • Centro de Estudios Clínicos SAGA ( Site 0033)
    Santiago, Region M. de Santiago 7500653, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fundación Arturo López Pérez ( Site 0031)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56224205098
  • Pontificia Universidad Catolica de Chile ( Site 0032)
    Santiago, Region M. de Santiago 8330032, Chile
    Recruiting
    • Study Coordinator · Contact+56934331806
  • Bradford Hill Centro de Investigaciones Clinicas ( Site 0030)
    Santiago, Region M. de Santiago 8420383, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peking University First Hospital ( Site 0180)
    Beijing, Beijing Municipality 100034, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chongqing Cancer Hospital ( Site 0186)
    Chongqing, Chongqing Municipality 400030, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hunan Cancer Hospital ( Site 0181)
    Changsha, Hunan 410013, China
    Recruiting
    • Study Coordinator · Contact073188651900
  • The First Hospital of Jilin University ( Site 0185)
    Changchun, Jilin 130021, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • West China Hospital Sichuan University ( Site 0187)
    Chengdu, Sichuan 610041, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Paoli Calmettes ( Site 0053)
    Marseille, Bouches-du-Rhone 13273, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054)
    Rennes, Ille-et-Vilaine 35000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Oscar Lambret ( Site 0051)
    Lille, Nord 59000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gustave Roussy ( Site 0050)
    Villejuif, Val-de-Marne 94800, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Rambam Health Care Campus ( Site 0082)
    Haifa, 3109601, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Rabin Medical Center ( Site 0081)
    Petah Tikva, 4941492, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sheba Medical Center ( Site 0080)
    Ramat Gan, 5265601, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Cancer Center Hospital East ( Site 0190)
    Kashiwa, Chiba 277-8577, Japan
    Recruiting
    • Study Coordinator · Contact+81-4-7133-1111
  • Cancer Institute Hospital of JFCR ( Site 0192)
    Koto, Tokyo 135-8550, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0191)
    Osaka, 541-8567, Japan
    Recruiting
    • Study Coordinator · Contact+81-6-6945-1181
  • Radboudumc ( Site 0091)
    Nijmegen, Gelderland 6525 GA, Netherlands
    Recruiting
    • Study Coordinator · Contact+31 24 361 0353
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090)
    Amsterdam, North Holland 1066 CX, Netherlands
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Amsterdam UMC, locatie VUmc ( Site 0093)
    Amsterdam, North Holland 1081HV, Netherlands
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Erasmus Medisch Centrum ( Site 0092)
    Rotterdam, South Holland 3015 GD, Netherlands
    Recruiting
    • Study Coordinator · Contact+31 10 704 0252
  • Pratia Poznan ( Site 0105)
    Poznan, Greater Poland Voivodeship 60-192, Poland
    Recruiting
    • Study Coordinator · Contact+48506969916
  • Pratia MCM Krakow ( Site 0106)
    Krakow, Lesser Poland Voivodeship 30-727, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Narodowy Instytut Onkologii ( Site 0100)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact+48225463381
  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0104)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
    Recruiting
    • Study Coordinator · Contact+48943488930
  • Seoul National University Hospital ( Site 0150)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact+82220720795
  • Severance Hospital Yonsei University Health System ( Site 0151)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact82-2-393-3652
  • Asan Medical Center ( Site 0153)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact02-3010-3266
  • Samsung Medical Center ( Site 0152)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82234103438
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0113)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • HOSPITAL CLÍNIC DE BARCELONA ( Site 0112)
    Barcelona, Catalonia 08036, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111)
    Madrid, Madrid, Comunidad de 28040, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Virgen de la Victoria ( Site 0114)
    Málaga, 29016, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chi Mei Medical Center ( Site 0162)
    Tainan, Tainan 71004, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Cheng Kung University Hospital ( Site 0161)
    Tainan, 704, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Taiwan University Hospital ( Site 0160)
    Taipei, 10002, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ankara Bilkent Şehir Hastanesi. ( Site 0131)
    Çankaya, Ankara 06800, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ankara University Health Practice and Research Hospitals ( Site 0134)
    Ankara, 06620, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 312 595 71 39
  • Hacettepe Universite Hastaneleri ( Site 0130)
    Ankara, 6230, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 312 305 43 30
  • Koc University, School of Medicine ( Site 0133)
    Istanbul, 34010, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact0212 467 87 00.
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2028, 34 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 34 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Primary completion moved twice since we started tracking on Sep 25, 2026: Oct 2028 → Feb 2028, last on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 10, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Feb 8, 2028was Oct 2028
CompletionEst.
Mar 25, 2031
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 25 sites changed recruiting status (25 now active, not recruiting)
Show 25 sites
  • Peking University First Hospital ( Site 0180) · Beijing, ChinaRecruiting→Active, not recruiting
  • Chongqing Cancer Hospital ( Site 0186) · Chongqing, ChinaRecruiting→Active, not recruiting
  • West China Hospital Sichuan University ( Site 0187) · Chengdu, ChinaRecruiting→Active, not recruiting
  • Rambam Health Care Campus ( Site 0082) · Haifa, IsraelRecruiting→Active, not recruiting
  • Rabin Medical Center ( Site 0081) · Petah Tikva, IsraelRecruiting→Active, not recruiting
  • Sheba Medical Center ( Site 0080) · Ramat Gan, IsraelRecruiting→Active, not recruiting
  • National Cheng Kung University Hospital ( Site 0161) · Tainan, TaiwanRecruiting→Active, not recruiting
  • National Taiwan University Hospital ( Site 0160) · Taipei, TaiwanRecruiting→Active, not recruiting
  • The First Hospital of Jilin University ( Site 0185) · Changchun, ChinaRecruiting→Active, not recruiting
  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054) · Rennes, FranceRecruiting→Active, not recruiting
  • Cancer Institute Hospital of JFCR ( Site 0192) · Koto, JapanRecruiting→Active, not recruiting
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 0112) · Barcelona, SpainRecruiting→Active, not recruiting
  • Chi Mei Medical Center ( Site 0162) · Tainan, TaiwanRecruiting→Active, not recruiting
  • Ankara Bilkent Şehir Hastanesi. ( Site 0131) · Çankaya, Turkey (Türkiye)Recruiting→Active, not recruiting
  • Centro de Estudios Clínicos SAGA ( Site 0033) · Santiago, ChileRecruiting→Active, not recruiting
  • Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) · Santiago, ChileRecruiting→Active, not recruiting
  • Institut Paoli Calmettes ( Site 0053) · Marseille, FranceRecruiting→Active, not recruiting
  • Centre Oscar Lambret ( Site 0051) · Lille, FranceRecruiting→Active, not recruiting
  • Gustave Roussy ( Site 0050) · Villejuif, FranceRecruiting→Active, not recruiting
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090) · Amsterdam, NetherlandsRecruiting→Active, not recruiting
  • Amsterdam UMC, locatie VUmc ( Site 0093) · Amsterdam, NetherlandsRecruiting→Active, not recruiting
  • Pratia MCM Krakow ( Site 0106) · Krakow, PolandRecruiting→Active, not recruiting
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0113) · L'Hospitalet de Llobregat, SpainRecruiting→Active, not recruiting
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111) · Madrid, SpainRecruiting→Active, not recruiting
  • Hospital Universitario Virgen de la Victoria ( Site 0114) · Málaga, SpainRecruiting→Active, not recruiting
Show site
  • Fundación Arturo López Pérez ( Site 0031) · Santiago, Chile
Show 1 removed
  • FALP ( Site 0031) · Santiago, Chile
across 4 updates, Oct 6, 2026 – Nov 13, 2026
Primary completion
Oct 25, 2028→Feb 8, 2028
moved 2 times, Oct 6, 2026 – Oct 28, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants Who Experience an Adverse Event (AE)Up to approximately 43 months → Up to approximately 19 months
  • Time frameNumber of Participants Who Discontinue Study Treatment Due to an AEUp to approximately 42 months → Up to approximately 18 months
Oct 28, 2026
Secondary outcomes
1 time frame changed, 12 removed
What changed in the outcomes
  • RemovedDuration Of Response (DOR) Per RECIST 1.1 as Assessed by the InvestigatorTime frame: Up to approximately 72 months
  • RemovedProgression-free Survival (PFS) Per RECIST 1.1 as Assessed by the InvestigatorTime frame: Up to approximately 72 months
  • RemovedOverall Survival (OS) Per RECIST 1.1 as Assessed by the InvestigatorTime frame: Up to approximately 72 months
  • RemovedArea Under the Concentration-Time Curve (AUC) of MK-3120 Antibody-Drug Conjugate (ADC)Time frame: At specified time points up to approximately 43 months
  • RemovedAUC of MK-3120 Total Antibody (TAb)Time frame: At specified time points up to approximately 43 months
  • RemovedAUC of MK-3120 Free PayloadTime frame: At specified time points up to approximately 43 months
  • RemovedMaximum Concentration (Cmax) of MK-3120 ADCTime frame: At specified time points up to approximately 43 months
  • RemovedCmax of MK-3120 TAbTime frame: At specified time points up to approximately 43 months
  • RemovedCmax of MK-3120 Free PayloadTime frame: At specified time points up to approximately 43 months
  • RemovedMinimum Concentration (Cmin) of MK-3120 ADCTime frame: At specified time points up to approximately 43 months
  • RemovedCmin of MK-3120 TAbTime frame: At specified time points up to approximately 43 months
  • RemovedCmin of MK-3120 Free PayloadTime frame: At specified time points up to approximately 43 months
  • Time frameObjective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as Assessed by the InvestigatorUp to approximately 72 months → Up to approximately 48 months
Oct 28, 2026
Site contacts
Changed at 25 sites. See the sites
Show 25 sites
  • Peking University First Hospital ( Site 0180) · Beijing, ChinaContact removed •••2211
  • Chongqing Cancer Hospital ( Site 0186) · Chongqing, ChinaContact removed •••9277
  • West China Hospital Sichuan University ( Site 0187) · Chengdu, ChinaContact removed •••1141
  • Rambam Health Care Campus ( Site 0082) · Haifa, IsraelContact removed •••6234
  • Rabin Medical Center ( Site 0081) · Petah Tikva, IsraelContact removed •••8110
  • Sheba Medical Center ( Site 0080) · Ramat Gan, IsraelContact removed •••4498
  • National Cheng Kung University Hospital ( Site 0161) · Tainan, TaiwanContact removed •••3535
  • National Taiwan University Hospital ( Site 0160) · Taipei, TaiwanContact removed •••3456
  • The First Hospital of Jilin University ( Site 0185) · Changchun, ChinaContact removed •••3330
  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054) · Rennes, FranceContact removed •••3196
  • Cancer Institute Hospital of JFCR ( Site 0192) · Koto, JapanContact removed •••0111
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 0112) · Barcelona, SpainContact removed •••4208
  • Chi Mei Medical Center ( Site 0162) · Tainan, TaiwanContact removed •••3571
  • Ankara Bilkent Şehir Hastanesi. ( Site 0131) · Çankaya, Turkey (Türkiye)Contact removed •••6271
  • Centro de Estudios Clínicos SAGA ( Site 0033) · Santiago, ChileContact removed •••2199
  • Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) · Santiago, ChileContact removed •••0970
  • Institut Paoli Calmettes ( Site 0053) · Marseille, FranceContact removed •••3789
  • Centre Oscar Lambret ( Site 0051) · Lille, FranceContact removed •••5959
  • Gustave Roussy ( Site 0050) · Villejuif, FranceContact removed •••4211
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090) · Amsterdam, NetherlandsContact removed •••2446
  • Amsterdam UMC, locatie VUmc ( Site 0093) · Amsterdam, NetherlandsContact removed •••4875
  • Pratia MCM Krakow ( Site 0106) · Krakow, PolandContact removed •••4100
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0113) · L'Hospitalet de Llobregat, SpainContact removed •••3261
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111) · Madrid, SpainContact removed •••2805
  • Hospital Universitario Virgen de la Victoria ( Site 0114) · Málaga, SpainContact removed •••2508
across 4 updates, Oct 6, 2026 – Nov 13, 2026
Show all 4 updates
  1. Nov 13, 2026
    4 sites changed recruiting status (4 now active, not recruiting)
    Show 4 sites
    • Pratia MCM Krakow ( Site 0106) · Krakow, PolandRecruiting→Active, not recruiting
    • Institut Català d'Oncologia - L'Hospitalet ( Site 0113) · L'Hospitalet de Llobregat, SpainRecruiting→Active, not recruiting
    • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111) · Madrid, SpainRecruiting→Active, not recruiting
    • Hospital Universitario Virgen de la Victoria ( Site 0114) · Málaga, SpainRecruiting→Active, not recruiting
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Pratia MCM Krakow ( Site 0106) · Krakow, PolandContact removed •••4100
    • Institut Català d'Oncologia - L'Hospitalet ( Site 0113) · L'Hospitalet de Llobregat, SpainContact removed •••3261
    • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0111) · Madrid, SpainContact removed •••2805
    • Hospital Universitario Virgen de la Victoria ( Site 0114) · Málaga, SpainContact removed •••2508
  2. Nov 10, 2026
    7 sites changed recruiting status (7 now active, not recruiting)
    Show 7 sites
    • Centro de Estudios Clínicos SAGA ( Site 0033) · Santiago, ChileRecruiting→Active, not recruiting
    • Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) · Santiago, ChileRecruiting→Active, not recruiting
    • Institut Paoli Calmettes ( Site 0053) · Marseille, FranceRecruiting→Active, not recruiting
    • Centre Oscar Lambret ( Site 0051) · Lille, FranceRecruiting→Active, not recruiting
    • Gustave Roussy ( Site 0050) · Villejuif, FranceRecruiting→Active, not recruiting
    • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090) · Amsterdam, NetherlandsRecruiting→Active, not recruiting
    • Amsterdam UMC, locatie VUmc ( Site 0093) · Amsterdam, NetherlandsRecruiting→Active, not recruiting
    Site contacts Changed at 7 sites. See the sites
    Show 7 sites
    • Centro de Estudios Clínicos SAGA ( Site 0033) · Santiago, ChileContact removed •••2199
    • Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) · Santiago, ChileContact removed •••0970
    • Institut Paoli Calmettes ( Site 0053) · Marseille, FranceContact removed •••3789
    • Centre Oscar Lambret ( Site 0051) · Lille, FranceContact removed •••5959
    • Gustave Roussy ( Site 0050) · Villejuif, FranceContact removed •••4211
    • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0090) · Amsterdam, NetherlandsContact removed •••2446
    • Amsterdam UMC, locatie VUmc ( Site 0093) · Amsterdam, NetherlandsContact removed •••4875
    + 1 other change: verification date
  3. Oct 28, 2026
    6 sites changed recruiting status (6 now active, not recruiting)
    Show 6 sites
    • The First Hospital of Jilin University ( Site 0185) · Changchun, ChinaRecruiting→Active, not recruiting
    • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054) · Rennes, FranceRecruiting→Active, not recruiting
    • Cancer Institute Hospital of JFCR ( Site 0192) · Koto, JapanRecruiting→Active, not recruiting
    • HOSPITAL CLÍNIC DE BARCELONA ( Site 0112) · Barcelona, SpainRecruiting→Active, not recruiting
    • Chi Mei Medical Center ( Site 0162) · Tainan, TaiwanRecruiting→Active, not recruiting
    • Ankara Bilkent Şehir Hastanesi. ( Site 0131) · Çankaya, Turkey (Türkiye)Recruiting→Active, not recruiting
    Primary completion Mar 7, 2031→Feb 8, 2028
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants Who Experience an Adverse Event (AE)Up to approximately 43 months → Up to approximately 19 months
    • Time frameNumber of Participants Who Discontinue Study Treatment Due to an AEUp to approximately 42 months → Up to approximately 18 months
    Secondary outcomes 1 time frame changed, 12 removed
    What changed in the outcomes
    • RemovedDuration Of Response (DOR) Per RECIST 1.1 as Assessed by the InvestigatorTime frame: Up to approximately 72 months
    • RemovedProgression-free Survival (PFS) Per RECIST 1.1 as Assessed by the InvestigatorTime frame: Up to approximately 72 months
    • RemovedOverall Survival (OS) Per RECIST 1.1 as Assessed by the InvestigatorTime frame: Up to approximately 72 months
    • RemovedArea Under the Concentration-Time Curve (AUC) of MK-3120 Antibody-Drug Conjugate (ADC)Time frame: At specified time points up to approximately 43 months
    • RemovedAUC of MK-3120 Total Antibody (TAb)Time frame: At specified time points up to approximately 43 months
    • RemovedAUC of MK-3120 Free PayloadTime frame: At specified time points up to approximately 43 months
    • RemovedMaximum Concentration (Cmax) of MK-3120 ADCTime frame: At specified time points up to approximately 43 months
    • RemovedCmax of MK-3120 TAbTime frame: At specified time points up to approximately 43 months
    • RemovedCmax of MK-3120 Free PayloadTime frame: At specified time points up to approximately 43 months
    • RemovedMinimum Concentration (Cmin) of MK-3120 ADCTime frame: At specified time points up to approximately 43 months
    • RemovedCmin of MK-3120 TAbTime frame: At specified time points up to approximately 43 months
    • RemovedCmin of MK-3120 Free PayloadTime frame: At specified time points up to approximately 43 months
    • Time frameObjective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as Assessed by the InvestigatorUp to approximately 72 months → Up to approximately 48 months
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • The First Hospital of Jilin University ( Site 0185) · Changchun, ChinaContact removed •••3330
    • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054) · Rennes, FranceContact removed •••3196
    • Cancer Institute Hospital of JFCR ( Site 0192) · Koto, JapanContact removed •••0111
    • HOSPITAL CLÍNIC DE BARCELONA ( Site 0112) · Barcelona, SpainContact removed •••4208
    • Chi Mei Medical Center ( Site 0162) · Tainan, TaiwanContact removed •••3571
    • Ankara Bilkent Şehir Hastanesi. ( Site 0131) · Çankaya, Turkey (Türkiye)Contact removed •••6271
    + 1 other change: references
  4. Oct 6, 2026
    1 site added, 1 site removed. 8 sites changed recruiting status (8 now active, not recruiting)
    Show 8 sites
    • Peking University First Hospital ( Site 0180) · Beijing, ChinaRecruiting→Active, not recruiting
    • Chongqing Cancer Hospital ( Site 0186) · Chongqing, ChinaRecruiting→Active, not recruiting
    • West China Hospital Sichuan University ( Site 0187) · Chengdu, ChinaRecruiting→Active, not recruiting
    • Rambam Health Care Campus ( Site 0082) · Haifa, IsraelRecruiting→Active, not recruiting
    • Rabin Medical Center ( Site 0081) · Petah Tikva, IsraelRecruiting→Active, not recruiting
    • Sheba Medical Center ( Site 0080) · Ramat Gan, IsraelRecruiting→Active, not recruiting
    • National Cheng Kung University Hospital ( Site 0161) · Tainan, TaiwanRecruiting→Active, not recruiting
    • National Taiwan University Hospital ( Site 0160) · Taipei, TaiwanRecruiting→Active, not recruiting
    Show site
    • Fundación Arturo López Pérez ( Site 0031) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0031) · Santiago, Chile
    Primary completion Oct 25, 2028→Mar 7, 2031
    Site contacts Changed at 8 sites. See the sites
    Show 8 sites
    • Peking University First Hospital ( Site 0180) · Beijing, ChinaContact removed •••2211
    • Chongqing Cancer Hospital ( Site 0186) · Chongqing, ChinaContact removed •••9277
    • West China Hospital Sichuan University ( Site 0187) · Chengdu, ChinaContact removed •••1141
    • Rambam Health Care Campus ( Site 0082) · Haifa, IsraelContact removed •••6234
    • Rabin Medical Center ( Site 0081) · Petah Tikva, IsraelContact removed •••8110
    • Sheba Medical Center ( Site 0080) · Ramat Gan, IsraelContact removed •••4498
    • National Cheng Kung University Hospital ( Site 0161) · Tainan, TaiwanContact removed •••3535
    • National Taiwan University Hospital ( Site 0160) · Taipei, TaiwanContact removed •••3456
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06818643
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Mar 25, 2025
Primary completion
Feb 8, 2028 (estimated)
Completion
Mar 25, 2031 (estimated)
Last update
Nov 13, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-nectin-4 Antibody-drug Conjugate MK-3120

Start the discussion